The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users
- PMID: 25041346
- PMCID: PMC4229435
- DOI: 10.1111/add.12682
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users
Abstract
Aims: To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users.
Design: A generalized estimating equation model assuming a binomial distribution and a logit-link function was used to examine for a possible protective effect of MMT use on HCV incidence.
Setting: Data from three prospective cohort studies of illicit drug users in Vancouver, Canada between 1996 and 2012.
Participants: A total of 1004 HCV antibody-negative illicit drug users stratified by exposure to MMT.
Measurements: Baseline and semi-annual HCV antibody testing and standardized interviewer-administered questionnaire soliciting self-reported data relating to drug use patterns, risk behaviors, detailed socio-demographic data and status of active participation in an MMT program.
Findings: One hundred and eighty-four HCV seroconversions were observed for an HCV incidence density of 6.32 [95% confidence interval (CI) = 5.44-7.31] per 100 person-years. After adjusting for potential confounders, MMT exposure was protective against HCV seroconversion [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29-0.76]. In subanalyses, a dose-response protective effect of increasing MMT exposure on HCV incidence (AOR = 0.87; 95% CI = 0.78-0.97) per increasing 6-month period exposed to MMT was observed.
Conclusion: Participation in methadone maintenance treatment appears to be highly protective against hepatitis C incidence among illicit drug users. There appears to be a dose-response protective effect of increasing methadone exposure on hepatitis C incidence.
Keywords: HCV; hepatitis C; illicit drug use; incident infection; methadone; opioid; seroconversion.
© 2014 Society for the Study of Addiction.
Comment in
-
Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?Addiction. 2014 Dec;109(12):2060-1. doi: 10.1111/add.12750. Addiction. 2014. PMID: 25384936 Free PMC article. No abstract available.
Similar articles
-
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.Addiction. 2015 May;110(5):796-802. doi: 10.1111/add.12836. Epub 2015 Jan 22. Addiction. 2015. PMID: 25529103 Free PMC article.
-
Low risk for hepatitis C seroconversion in methadone maintenance treatment.J Addict Med. 2011 Sep;5(3):214-20. doi: 10.1097/ADM.0b013e31820e13dd. J Addict Med. 2011. PMID: 21844836
-
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.JAMA Intern Med. 2014 Dec;174(12):1974-81. doi: 10.1001/jamainternmed.2014.5416. JAMA Intern Med. 2014. PMID: 25347412 Free PMC article.
-
Side Effects of Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements.Curr Drug Saf. 2023;18(2):167-174. doi: 10.2174/1574886317666220514154931. Curr Drug Saf. 2023. PMID: 35570535
-
Tuberculosis and illicit drug use: review and update.Clin Infect Dis. 2009 Jan 1;48(1):72-82. doi: 10.1086/594126. Clin Infect Dis. 2009. PMID: 19046064 Free PMC article. Review.
Cited by
-
Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review From Animal and Human Studies.Front Immunol. 2019 Dec 12;10:2914. doi: 10.3389/fimmu.2019.02914. eCollection 2019. Front Immunol. 2019. PMID: 31921173 Free PMC article. Review.
-
Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.Subst Use Misuse. 2022;57(7):1144-1153. doi: 10.1080/10826084.2022.2064509. Epub 2022 Apr 21. Subst Use Misuse. 2022. PMID: 35443862 Free PMC article.
-
Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.J Viral Hepat. 2018 Jan;25(1):28-36. doi: 10.1111/jvh.12758. Epub 2017 Sep 4. J Viral Hepat. 2018. PMID: 28719060 Free PMC article.
-
Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.Am J Trop Med Hyg. 2017 Dec;97(6):1920-1928. doi: 10.4269/ajtmh.17-0019. Epub 2017 Oct 12. Am J Trop Med Hyg. 2017. PMID: 29141707 Free PMC article.
-
Medical Detoxification for Nonopioid Substances Is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment.J Addict Med. 2022 Nov-Dec 01;16(6):653-658. doi: 10.1097/ADM.0000000000000984. J Addict Med. 2022. PMID: 35245917 Free PMC article.
References
-
- Haydon E, Fischer B, Krajden M. Hepatitis C Virus (HCV) infection and illicit drug use [Internet] Canadian Centre of Substance abuse; Ottawa: 2005. cited 2014 Jan 18]. Available from: http://www.ccsa.ca/2005CCSADocuments/ccsa-004030-2005.pdf, Archived at http://www.webcitation.org/6QS7hPs7j on June 19th, 2014.
-
- Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342. - PubMed
-
- Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21S–28S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R03 DA033851/DA/NIDA NIH HHS/United States
- R01 DA028532/DA/NIDA NIH HHS/United States
- R25 DA033211/DA/NIDA NIH HHS/United States
- R01 DA036307/DA/NIDA NIH HHS/United States
- R01 DA011591/DA/NIDA NIH HHS/United States
- R03DA033851-01/DA/NIDA NIH HHS/United States
- R01DA036307/DA/NIDA NIH HHS/United States
- R01 DA021525/DA/NIDA NIH HHS/United States
- R25 DA037756/DA/NIDA NIH HHS/United States
- R01DA011591/DA/NIDA NIH HHS/United States
- MOP-125948/CAPMC/ CIHR/Canada
- R01DA021525/DA/NIDA NIH HHS/United States
- R01DA028532/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical